These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 12481437)

  • 1. Attenuated recombinant vaccinia virus expressing oncofetal antigen (tumor-associated antigen) 5T4 induces active therapy of established tumors.
    Mulryan K; Ryan MG; Myers KA; Shaw D; Wang W; Kingsman SM; Stern PL; Carroll MW
    Mol Cancer Ther; 2002 Oct; 1(12):1129-37. PubMed ID: 12481437
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Active treatment of murine tumors with a highly attenuated vaccinia virus expressing the tumor associated antigen 5T4 (TroVax) is CD4+ T cell dependent and antibody mediated.
    Harrop R; Ryan MG; Myers KA; Redchenko I; Kingsman SM; Carroll MW
    Cancer Immunol Immunother; 2006 Sep; 55(9):1081-90. PubMed ID: 16311730
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination of vaccination and chimeric receptor expressing T cells provides improved active therapy of tumors.
    Jiang HR; Gilham DE; Mulryan K; Kirillova N; Hawkins RE; Stern PL
    J Immunol; 2006 Oct; 177(7):4288-98. PubMed ID: 16982863
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 5T4-modified vaccinia ankara: progress in tumor-associated antigen-based immunotherapy.
    Amato RJ
    Expert Opin Biol Ther; 2007 Sep; 7(9):1463-9. PubMed ID: 17727334
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 5T4-modified vaccinia Ankara: progress in tumor-associated antigen-based immunotherapy.
    Amato RJ
    Expert Opin Biol Ther; 2010 Feb; 10(2):281-7. PubMed ID: 20088718
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of the murine 5T4 oncofoetal antigen: a target for immunotherapy in cancer.
    Woods AM; Wang WW; Shaw DM; Ward CM; Carroll MW; Rees BR; Stern PL
    Biochem J; 2002 Aug; 366(Pt 1):353-65. PubMed ID: 12003637
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Murine responses to recombinant MVA versus ALVAC vaccines against tumor-associated antigens, gp100 and 5T4.
    Hanwell DG; McNeil B; Visan L; Rodrigues L; Dunn P; Shewen PE; Macallum GE; Turner PV; Vogel TU
    J Immunother; 2013 May; 36(4):238-47. PubMed ID: 23603858
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 5T4 oncofoetal glycoprotein: an old target for a novel prostate cancer immunotherapy.
    Cappuccini F; Pollock E; Stribbling S; Hill AVS; Redchenko I
    Oncotarget; 2017 Jul; 8(29):47474-47489. PubMed ID: 28537896
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Highly attenuated modified vaccinia virus Ankara (MVA) as an effective recombinant vector: a murine tumor model.
    Carroll MW; Overwijk WW; Chamberlain RS; Rosenberg SA; Moss B; Restifo NP
    Vaccine; 1997 Mar; 15(4):387-94. PubMed ID: 9141209
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of MVA-5T4 as a novel immunotherapeutic vaccine in colorectal, renal and prostate cancer.
    Amato RJ; Stepankiw M
    Future Oncol; 2012 Mar; 8(3):231-7. PubMed ID: 22409460
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of Modified Vaccinia Ankara-5T4 and Low-Dose Cyclophosphamide on Antitumor Immunity in Metastatic Colorectal Cancer: A Randomized Clinical Trial.
    Scurr M; Pembroke T; Bloom A; Roberts D; Thomson A; Smart K; Bridgeman H; Adams R; Brewster A; Jones R; Gwynne S; Blount D; Harrop R; Wright M; Hills R; Gallimore A; Godkin A
    JAMA Oncol; 2017 Oct; 3(10):e172579. PubMed ID: 28880972
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A randomized phase II trial to examine modified vaccinia Ankara-5T4 vaccine in patients with relapsed asymptomatic ovarian cancer (TRIOC).
    Michael A; Wilson W; Sunshine S; Annels N; Harrop R; Blount D; Pandha H; Lord R; Ngai Y; Nicum S; Stylianou L; Gwyther S; McNeish IA; Hackshaw A; Ledermann J
    Int J Gynecol Cancer; 2024 Aug; 34(8):1225-1231. PubMed ID: 38760075
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CD4+ T-cell recognition of human 5T4 oncofoetal antigen: implications for initial depletion of CD25+ T cells.
    Elkord E; Burt DJ; Drijfhout JW; Hawkins RE; Stern PL
    Cancer Immunol Immunother; 2008 Jun; 57(6):833-47. PubMed ID: 18004564
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sequential administration of MVA-based vaccines and PD-1/PD-L1-blocking antibodies confers measurable benefits on tumor growth and survival: Preclinical studies with MVA-βGal and MVA-MUC1 (TG4010) in a murine tumor model.
    Remy-Ziller C; Thioudellet C; Hortelano J; Gantzer M; Nourtier V; Claudepierre MC; Sansas B; Préville X; Bendjama K; Quemeneur E; Rittner K
    Hum Vaccin Immunother; 2018 Jan; 14(1):140-145. PubMed ID: 28925793
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vaccination of colorectal cancer patients with modified vaccinia Ankara delivering the tumor antigen 5T4 (TroVax) induces immune responses which correlate with disease control: a phase I/II trial.
    Harrop R; Connolly N; Redchenko I; Valle J; Saunders M; Ryan MG; Myers KA; Drury N; Kingsman SM; Hawkins RE; Carroll MW
    Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3416-24. PubMed ID: 16740766
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vaccination of colorectal cancer patients with modified vaccinia ankara encoding the tumor antigen 5T4 (TroVax) given alongside chemotherapy induces potent immune responses.
    Harrop R; Drury N; Shingler W; Chikoti P; Redchenko I; Carroll MW; Kingsman SM; Naylor S; Melcher A; Nicholls J; Wassan H; Habib N; Anthoney A
    Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4487-94. PubMed ID: 17671134
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II trial of Modified Vaccinia Ankara (MVA) virus expressing 5T4 and high dose Interleukin-2 (IL-2) in patients with metastatic renal cell carcinoma.
    Kaufman HL; Taback B; Sherman W; Kim DW; Shingler WH; Moroziewicz D; DeRaffele G; Mitcham J; Carroll MW; Harrop R; Naylor S; Kim-Schulze S
    J Transl Med; 2009 Jan; 7():2. PubMed ID: 19128501
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vaccination with recombinant modified vaccinia virus Ankara prevents the onset of intestinal allergy in mice.
    Bohnen C; Wangorsch A; Schülke S; Nakajima-Adachi H; Hachimura S; Burggraf M; Süzer Y; Schwantes A; Sutter G; Waibler Z; Reese G; Toda M; Scheurer S; Vieths S
    Allergy; 2013 Aug; 68(8):1021-8. PubMed ID: 23909913
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vaccination of renal cell cancer patients with modified vaccinia Ankara delivering the tumor antigen 5T4 (TroVax) alone or administered in combination with interferon-alpha (IFN-alpha): a phase 2 trial.
    Amato RJ; Shingler W; Goonewardena M; de Belin J; Naylor S; Jac J; Willis J; Saxena S; Hernandez-McClain J; Harrop R
    J Immunother; 2009 Sep; 32(7):765-72. PubMed ID: 19561532
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cross-trial analysis of immunologic and clinical data resulting from phase I and II trials of MVA-5T4 (TroVax) in colorectal, renal, and prostate cancer patients.
    Harrop R; Shingler W; Kelleher M; de Belin J; Treasure P
    J Immunother; 2010; 33(9):999-1005. PubMed ID: 20948436
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.